SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Amphastar Pharmaceuticals, Inc. (AMPH) trades at a trailing P/E of 9.7, forward P/E of 6.5. Trailing earnings yield is 10.30%, forward earnings yield 15.29%. PEG 0.11 (Peter Lynch undervalued ≤1.0). Graham Number is $28.74.
Criteria proven by this page:
- VALUE (84/100, Pass) — P/E is below market average (9.7); PEG ≤ 1.0 — Peter Lynch undervalued (0.11); analyst target implies upside (+40.3%); earnings yield beats bond yields (10.30%).
- Forward P/E 6.5 (down from trailing 9.7) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.11 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 10.30% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 15.29% as earnings recover.
- Analyst consensus target $30.00 (+40.3% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 71/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
84/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AMPH
Valuation Multiples
P/E (TTM)9.7
Forward P/E6.5
PEG Ratio0.11
Forward PEG0.11
P/B Ratio1.21
P/S Ratio1.32
EV/EBITDA7.4
Per Share Data
EPS (TTM)$2.14
Forward EPS (Est.)$3.27
Book Value / Share$17.18
Revenue / Share$15.68
FCF / Share$2.64
Yields & Fair Value
Earnings Yield10.30%
Forward Earnings Yield15.29%
Dividend Yield0.00%
Graham Number$28.74
SharesGrow IV$35.53 (+66.2%)
Analyst Target$30.00 (+40.3%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
79.4 |
-0.17 |
2.54 |
3.28 |
- |
| 2017 |
196.8 |
-3.48 |
2.63 |
3.69 |
- |
| 2018 |
-160.9 |
0.73 |
2.78 |
3.13 |
- |
| 2019 |
18.5 |
-0.02 |
2.38 |
2.81 |
- |
| 2020 |
674.2 |
-6.94 |
2.35 |
2.70 |
- |
| 2021 |
17.9 |
0.00 |
2.50 |
2.54 |
- |
| 2022 |
14.9 |
0.33 |
2.57 |
2.73 |
- |
| 2023 |
21.7 |
0.42 |
4.67 |
4.63 |
- |
| 2024 |
11.3 |
0.73 |
2.46 |
2.46 |
- |
| 2025 |
12.8 |
-0.35 |
1.59 |
1.74 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.22 |
$255.17M |
$10.53M |
4.1% |
| 2017 |
$0.09 |
$240.18M |
$4.51M |
1.9% |
| 2018 |
$-0.12 |
$294.67M |
$-5.74M |
-1.9% |
| 2019 |
$0.98 |
$322.36M |
$48.94M |
15.2% |
| 2020 |
$0.02 |
$349.85M |
$1.1M |
0.3% |
| 2021 |
$1.25 |
$437.77M |
$62.12M |
14.2% |
| 2022 |
$1.74 |
$498.99M |
$91.39M |
18.3% |
| 2023 |
$2.60 |
$644.4M |
$137.55M |
21.3% |
| 2024 |
$3.06 |
$712.81M |
$159.52M |
22.4% |
| 2025 |
$2.03 |
$719.89M |
$98.09M |
13.6% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$3.28 |
$3.17 – $3.46 |
$756.52M |
$746.77M – $766.26M |
3 |
| 2027 |
$3.49 |
$3.23 – $3.68 |
$792.55M |
$788.96M – $796.14M |
3 |
| 2028 |
$3.62 |
$3.52 – $3.70 |
$824.16M |
$824.14M – $824.18M |
1 |
| 2029 |
$3.02 |
$2.94 – $3.09 |
$881M |
$862.56M – $897.18M |
1 |
| 2030 |
$3.00 |
$2.92 – $3.07 |
$905M |
$886.06M – $921.63M |
1 |
